Nexstim sees that Innokas’ familiarity with the MedTech sector and flexible operation gives Innokas Medical a competitive edge

Nexstim Plc. develops and manufactures NBS equipment for demanding brain diagnostics. The NBS (Navigated Brain Stimulation) System combines 3D brain mapping, stimulation coil positioning, and magnetic stimulation. Nexstim’s NBS equipment has been delivered to clinical environments in hospitals and brain research centers around the world.

Innokas Medical and Nexstim had an extensive collaboration agreement where Innokas Medical was in charge of managing the delivery chains and manufacturing and delivering Nexstim’s NBS System 4 systems with their NexSpeech Modules and TMS II Stimulator Coils. Nexstim Oy’s former Managing Director Janne Huhtala says Nexstim chose Innokas Medical to be its partner after comparing several suppliers in Finland and abroad.

“Based on pre-decided criteria, Innokas Medical turned out to be the best alternative. Practical operation has proved this choice to be correct.”

“Based on pre-decided criteria, Innokas Medical turned out to be the best alternative. Practical operation has proved this choice to be correct. Important to us are seamless communication, flexibility, an understanding of the entity from our perspective, and the ability to fine-tune operation to our benefit”, Huhtala explains.

Huhtala particularly appreciates Innokkas Medical’s business savvy, especially in the medical sector, and the company’s flexible operation and open communication. Huhtala says familiarity with the sector and flexible operation gives Innokas Medical a competitive edge.

“Innokas Medical’s flexibility and understanding of the MedTech business are important to us, and they set Innokas Medical apart from its competitors. The company has addressed problems encountered along the way and the project as a whole has been a success. Innokas Medical’s staff comprehends business operation and communicates openly. Timetables are always critical in business operation, and any delays are addressed at Innokas Medical”, Huhtala continues.